09 Sep 2022 --- Successful rates of complete skin clearance via earlier treatment using Tremfya (guselkumab – a human antibody) in adults with moderate to severe plaque psoriasis were revealed in a study. The data was released by Janssen Pharmaceutical Companies of Johnson & Johnson, which first developed guselkumab and holds exclusive worldwide marketing rights to Tremfya.
